Inotek Pharmaceuticals Secures $18,000,000 Series D Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=d34e08eb-6cbd-4776-93b4-a3f16a4aab47&Preview=1 -
Date
6/11/2010 -
Company Name
Inotek Pharmaceuticals -
Mailing Address
33 Hayden Avenue 2nd Floor Lexington, MA 02421 -
Company Description
Inotek Pharmaceuticals Corporation is a private, high-growth, development-stage pharmaceutical company founded in 1996. The Company has leveraged its small molecule chemistry expertise to discover and develop a deep pipeline of therapeutics targeting cell death, DNA repair and inflammatory pathways. Inotek’s lead program is focused on blocking the nuclear DNA repair enzyme, poly (ADP-ribose) polymerase (or PARP), that has broad application in a variety of unmet medical needs. -
Website
http://www.inotekcorp.com -
Transaction Type
Venture Equity -
Transaction Amount
$18,000,000 -
Transaction Round
Series D -
Proceeds Purposes
Proceeds from the financing will be used to advance Inotek’s novel eye-drop INO-8875 through multiple-dose Phase 2 clinical trials in glaucoma. -
M&A Terms
-
Venture Investor
Devon Park Bioventures -
Venture Investor
Care Capital -
Venture Investor
Rho Ventures -
Venture Investor
MedImmune Ventures -
Venture Investor
Bio*One Capital
